Day: September 4, 2022

<div>POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial</div>

POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Written by Customer Service on . Posted in Public Companies.

Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. Hansen INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced data will be released at ESMO Congress 2022 in Paris, France about the efficacy and safety of PNT2002 in the lead-in cohort of the SPLASH trial. An abstract is now available on the ESMO congress website at https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal_2/presentation/list?q=1400P, and an e-poster which contains updated data will be published and presented on Sunday, September 11th. The poster is titled “Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific Membrane Antigen (PSMA) Therapy in Metastatic...

Continue reading

Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022

Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022

Written by Customer Service on . Posted in Public Companies.

Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reached Stable disease was observed in 10 of 27 evaluable patients in an unselected patient population Comprehensive pharmacodynamic studies indicate the activation of the innate as well as the adaptive immune system Well managed safety profile HEIDELBERG, Germany, Sept. 04, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with clinical trial results of its innate cell engager (ICE®) AFM24 has been accepted for a poster presentation at the Congress of the European Society for Medical Oncology (ESMO) from 9-13 September 2022 in Paris. The abstract...

Continue reading

Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports

Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports

Written by Customer Service on . Posted in Public Companies.

New prevalence figure 22–126% higher than previous estimates Prevalence expected to reach 592 million by 2050 Researchers urge global action on smoking cessation and air pollution reduction BARCELONA, Spain, Sept. 04, 2022 (GLOBE NEWSWIRE) — Over 480 million people worldwide likely suffer from chronic obstructive pulmonary disease, or COPD, according to a late-breaking abstract led by ResMed (NYSE: RMD, ASX: RMD) presented at the European Respiratory Society Congress today.1 This figure is 22–126% higher than today’s most cited estimates, which range from 212–392 million reported over the past decade.2,3,4 COPD is a chronic, progressive disease that restricts a person’s ability to breathe. Early-stage sufferers may use inhaled medications to reduce symptoms. Advanced stages may require supplemental oxygen or mechanical ventilation...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.